GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
May 11 2015 - 10:00AM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) "GW," "the Company"
or "the Group"), a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform, announced that Justin
Gover, GW's Chief Executive Officer, is scheduled to present at the
Bank of America Merrill Lynch 2015 Healthcare Conference to be held
at Encore at the Wynn in Las Vegas, NV on Tuesday, 12 May, 2015 at
4:20 p.m. PT.
A live audio webcast of the presentation will be available
through GW's corporate website in the investor relations section
from the investor's calendar of events page at www.gwpharm.com. A
replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 27 countries
outside the United States. GW is advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex®,
which is in Phase 3 clinical development for the treatment of
Dravet syndrome and Lennox-Gastaut syndrome and which is also
expected to enter Phase 3 clinical trials in the treatment of
Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
Enquiries: |
|
|
|
GW Pharmaceuticals plc |
(Today) +44 20 3727
1000 |
Stephen Schultz, VP Investor Relations
(U.S.) |
917 280 2424 / 401 500 6570 |
|
|
FTI Consulting (Media
Enquiries) |
|
Ben Atwell / Simon Conway / John Dineen
(UK) |
+ 44 20 3727 1000 |
Robert Stanislaro (U.S.) |
212 850 5657 |
|
|
Trout Group, LLC (U.S. investor
relations) |
|
Todd James / Chad Rubin |
646 378 2900 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024